Mesenchymal stromal cells from umbilical cord blood: improving in vitro selection and characterization for clinical use

Cytotherapy ◽  
2015 ◽  
Vol 17 (6) ◽  
pp. S42
Author(s):  
Eliana Amati ◽  
Sabrina Sella ◽  
Martina Bernardi ◽  
Elena Albiero ◽  
Silvia Castegnaro ◽  
...  
Cytotherapy ◽  
2015 ◽  
Vol 17 (11) ◽  
pp. 1506-1513 ◽  
Author(s):  
Hi-Jin You ◽  
Sik Namgoong ◽  
Seung-Kyu Han ◽  
Seong-Ho Jeong ◽  
Eun-Sang Dhong ◽  
...  

2009 ◽  
Vol 22 (05) ◽  
pp. 363-370 ◽  
Author(s):  
T. G. Koch ◽  
T. Heerkens ◽  
K. Besonov ◽  
P. D. Thomsen ◽  
D. H. Betts ◽  
...  

Summary Objective: Orthopaedic injury is the most common cause of lost training days or premature retirement in the equine athlete. Cell-based therapies are a potential new treatment option in musculo-skeletal diseases. Mesenchymal stromal cells (MSC) have been derived from multiple sources in the horse including bone marrow and umbilical cord blood. The objective of this study was to provide an in vitro comparison of the chondrogenic potential in MSC derived from adult bone marrow (BM-MSC) and umbilical cord blood (CB-MSC). Results: MSC from both sources produced tissue with cartilage-like morphology that stained positive for proteoglycans and expressed cartilage markers. The CB-MSC pellets were larger and showed hyaline-like cartilage morphology as early as day six. Gene expression of collagen type 21, aggrecan and CD-RAP was higher in CB- than BM-MSC pel-lets. Expression of Sox9 mRNA was similar between CB- and BM-MSC pellets. Protein concentration of cartilage-derived retinoic acid sensitive protein was higher in culture medium from CB- than BM-MSC pellets. Conclusion: CB-MSC and BM-MSC were both capable of producing hyaline-like cartilage in vitro. However, in this study the MSC from umbilical cord blood appeared to have more chondrogenic potential than the BMMSC based on the cells tested and parameters measured.Supplementary Information for this paper is available on the VCOT website at www.VCOTonline.com.


Cytotherapy ◽  
2009 ◽  
Vol 11 (7) ◽  
pp. 886-896 ◽  
Author(s):  
Patricia Flores-Guzmán ◽  
Eugenia Flores-Figueroa ◽  
Juan J. Montesinos ◽  
Guadalupe Martínez-Jaramillo ◽  
Veronica Fernández-Sánchez ◽  
...  

2009 ◽  
Vol 216 (2) ◽  
pp. 439-448 ◽  
Author(s):  
Isabel Zwart ◽  
Andrew J. Hill ◽  
Faisal Al-Allaf ◽  
Mili Shah ◽  
John Girdlestone ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Guadalupe R. Fajardo-Orduña ◽  
Héctor Mayani ◽  
Patricia Flores-Guzmán ◽  
Eugenia Flores-Figueroa ◽  
Erika Hernández-Estévez ◽  
...  

Mesenchymal stem/stromal cells (MSCs) from bone marrow (BM) have been used in coculture systems as a feeder layer for promoting the expansion of hematopoietic progenitor cells (HPCs) for hematopoietic cell transplantation. Because BM has some drawbacks, umbilical cord blood (UCB) and placenta (PL) have been proposed as possible alternative sources of MSCs. However, MSCs from UCB and PL sources have not been compared to determine which of these cell populations has the best capacity of promoting hematopoietic expansion. In this study, MSCs from UCB and PL were cultured under the same conditions to compare their capacities to support the expansion of HPCs in vitro. MSCs were cocultured with CD34+CD38−Lin− HPCs in the presence or absence of early acting cytokines. HPC expansion was analyzed through quantification of colony-forming cells (CFCs), long-term culture-initiating cells (LTC-ICs), and CD34+CD38−Lin− cells. MSCs from UCB and PL have similar capacities to increase HPC expansion, and this capacity is similar to that presented by BM-MSCs. Here, we are the first to determine that MSCs from UCB and PL have similar capacities to promote HPC expansion; however, PL is a better alternative source because MSCs can be obtained from a higher proportion of samples.


Sign in / Sign up

Export Citation Format

Share Document